China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a licensing agreement with its partner in Peru, which will handle the marketing of Mabwell’s MAILISHU (9MW0311) and MAIWEIJIAN (9MW0321), biosimilars of denosumab in Peru. Mabwell will retain responsibility for the development, manufacturing, and commercial supply of these products.
Biosimilars of Denosumab and Their Applications
9MW0321 is a proposed biosimilar of Xgeva (denosumab), and 9MW0311 is a proposed biosimilar of Prolia (denosumab). Denosumab, a novel RANKL inhibitor originally developed by Amgen, is currently marketed in China by BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235). MAILISHU received approval from the China National Medical Products Administration (NMPA) in March 2023, followed by MAIWEIJIAN in March 2024. These approvals mark a significant step forward in the availability of these treatments in China.
Mabwell’s Global Partnerships for Commercialization
Mabwell has strategically partnered with a number of overseas companies to facilitate the local commercialization of its products. This includes partnerships with Searle in Pakistan, Legrand in Colombia and Ecuador, Innobic in Asia, and others. These collaborations demonstrate Mabwell’s commitment to expanding access to its biosimilar products globally, enhancing patient access to critical therapies.-Fineline Info & Tech
Leave a Reply